These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 21628411)

  • 1. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
    Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
    Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Takami M; Katayama K; Noguchi K; Sugimoto Y
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity.
    Tibbitts DC; Escamilla-Powers JR; Zhang X; Sears RC
    Blood; 2012 May; 119(22):5334-5. PubMed ID: 22653959
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
    Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Oct; 59(4):749-52. PubMed ID: 22052829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
    Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
    [No Abstract]   [Full Text] [Related]  

  • 13. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
    Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
    Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
    Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.
    Giraud F; Bourhis M; Ebrahimi E; Herfindal L; Choudhury RR; Bjørnstad R; Døskeland SO; Anizon F; Moreau P
    Bioorg Med Chem; 2015 Nov; 23(22):7313-23. PubMed ID: 26526744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
    Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
    Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
    Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
    Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.